Recombinant Rat Gastric inhibitory polypeptide receptor (Gipr), partial (Active)

Using the mammalian cell expression system, CUSABIO has generated the recombinant rat gastric inhibitory polypeptide receptor (Gipr). The gene sequence corresponding to amino acids 19 to 135 of the rat Gipr protein is fused with a 10xHis-tag gene at the C-terminus. This combined gene sequence is then integrated into a plasmid vector and introduced into mammalian cells via transfection. Following transfection, the mammalian cells are cultivated to facilitate the expression of the protein. The resulting recombinant rat Gipr protein is harvested from the lysate of these cells. Its purity, determined by SDS-PAGE, exceeds 95%. The protein boasts low endotoxin levels, measuring below 1.0 EU/μg through the LAL method. Its functionality is validated through a functional ELISA. When immobilized at a concentration of 2 μg/mL, the Gipr protein effectively binds with the Anti-mouse Gipr recombinant antibody (CSB-RA009438MA1MO), exhibiting an EC₅₀ within the range of 6.946 to 8.740 ng/ml.

Gipr belongs to the class B1 G-protein-coupled receptor kinase and plays a crucial role in various aspects such as human adipose transformation, the proliferation of pancreatic β-cells, and insulin release, being associated with type 2 diabetes and obesity. Activation of the GIP-Gipr signaling pathway not only stimulates the secretion of insulin and glucagon-like peptide-1 but also promotes the proliferation and survival of pancreatic β-cells, playing a significant role in blood glucose regulation. Research has found a close correlation between the Gipr gene polymorphism and the occurrence of obesity. With the increasing demand in the obesity drug market, more drugs for obesity treatment are being developed. Mouse Gipr shares about 83% homology with human Gipr, and their structure and function are relatively similar. Therefore, preparing active mouse Gipr protein is beneficial for developing drugs with cross-species reactivity and advancing clinical drug research and development.